Inter-relationships between inflammatory markers in patients with stable COPD with bronchitis: Intra-patient and inter-patient variability

Thorax

Volumn 63, Issue 6, 2008, Pages 493-499

  Sapey, E ^a   Bayley, D ^a   Ahmad, A ^b   Newbold, P ^c   Snell, N ^c   Stockley, R A ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 1BETA; INTERLEUKIN 8; LEUKOTRIENE B4; MYELOPEROXIDASE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BRONCHITIS; CELL COUNT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; FEMALE; HUMAN; MALE; NEUTROPHIL COUNT; ONCOGENE; PRIORITY JOURNAL; SAMPLE SIZE; SPUTUM ANALYSIS;

AGED; BIOLOGICAL MARKERS; BRONCHITIS; CHEMOKINE CXCL1; CROSS-OVER STUDIES; CYTOKINES; FEMALE; HUMANS; LEUKOTRIENE B4; MALE; MIDDLE AGED; NEUTROPHILS; PEROXIDASE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPUTUM;

EID: 45149088260     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2007.086751     Document Type: Article

References (42)

1. do Boer W. Perspectives for cytokine antagonist therapy in COPD. Drug Discov Today 2005;10:93-106.
2. van der Vaart H, Koèter GH, Postma DS, et al. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:465-9.
3. Mahler DA, Huang S, Tabrizi M, et al. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD. A pilot study. Chest 2004;126:926-34.
4. Gompertz S, Stockley RA. A randomized, placebo-controlled trial of a leukotriene synthesis inhibitor in patients with COPD. Chest 2002;122:289-94.
5. Pinto-Plata V, Toso J, Lee K, et al. Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax 2006;61:23-8.
6. Franciosi LG, Page CP, Celli BR, et al. Markers of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2006;19:189-99.
7. Gompertz S, Bayley DL, Hill SL, et al. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax 2001;56:36-41.
8. Barnes PJ, Chowdhury B, Kharitonov SA, et al. Pulmonary perspective. Pulmonary biomarkers in COPD. Am J Respir Crit Care Med 2006;174:6-14.
9. Pauwels RA, Buist AS, Calverley PM, et al. GOLD Scientific Committee. Global strategy for the diagnosis, management and prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163:1256-76.
10. Anon. Definition and classification of chronic bronchitis for clinical and epidemiological purposes. A report to the Medical Research Council by their Committee on the aetiology of chronic bronchitis. Lancet 1965;1:775-9.
11. Woolhouse IS, Hill SL, Stockley RA. Symptom resolution assessed using a patient directed diary card during treatment of acute exacerbations of chronic bronchitis. Thorax 2001;56:947-53.
12. Woolhouse IS, Bayley DL, Stockley RA. Effect of sputum processing with dithiothreitol on the detection of inflammatory mediators in chronic bronchitis and bronchiectasis. Thorax 2002;57:667-71.
13. Snedecor GW, Cochran WG. Statistical methods. 8th ed. Ames: Iowa State Press, 1989.
14. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
15. Rodriquez-Roisin R. Towards a consenus definition of COPD exacerbation. Chest 2000;117(Suppl 2):398-401s.
16. Bhowmik A, Seemungal TA, Sapsford RJ, et al. Comparison of spontaneous and induced sputum for investigation of airway inflammation in chronic obstructive pulmonary disease. Thorax 1998;53:953-6.
17. Biernacki WA, Kharitonov SA, Barnes PJ. Increased leukotriene B4 and 8-isoprotane in exhaled breath condensate of patients with exacerbations of COPD. Thorax 2003;58:294-8.
18. Rutgers SR, Timens W, Kaufman HF, et al. Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. Eur Respir J 2000;15:109-15.
19. Pizzichini MM, Pizzichini E, Clelland L, et al. Prednisone-dependent asthma: inflammatory indices in induced sputum. Eur Respir J 1999;13:15-21.
20. Gamble E, Qiu Y, Wang D, et al. Variability of bronchial inflammation in chronic obstructive pulmonary disease: implications for study design. Eur Respir J 2006;27:293-9.
21. Beeh KM, Beier J, Kornmann O, et al. Long term repeatability of induced sputum cells and inflammatory markers in stable, moderately severe COPD. Chest 2003;123:778-83.
22. Effros RM, Su J, Casaburi R, et al. Utility of exhaled breath condensate in chronic obstructive pulmonary disease: a critical review. Curr Opin Pulm Med 2005;11:135-9.
23. Borrill Z, Starkey C, Vestbo J, et al. Reproducibility of exhaled breath condensate pH in chronic obstructive pulmonary disease. Eur Respir J 2005;25:269-74.
24. Effros RM, Peterson B, Casaburi R, et al. Epithelial lining fluid solute concentrations in chronic obstructive lung disease patients and normal subjects. J Appl Physiol 2005;99:1286-92
25. van Zuijlen DA, van de Graaf EA, van Bolhuis EM, et al. Measuring plasma exudation in nasal lavage fluid and in induced sputum as a tool for studying respiratory tract inflammation. J Intern Med 2001;256:1-10.
26. Persson CGA, Erjefalt JS, Greift L, et al. Plasma derived proteins in airway defence, disease and repair of epithelial injury. Eur Respir J 1998;11:958-70.
27. Erjefalt JS, Sundler F. Eosinophils, neutrophils and venular gaps in the airway mucosa at epithelial removal-restitution. Am J Respir Crit Care Med 1996;153:1666-74.
28. Traves SL, Culpitt S, Russell REK, et al. Elevated levels of the chemokines GROα and MCP-1 in sputum samples from COPD patients. Thorax 2002;57:590-5.
29. Sapey E, Bayley DL, Ahmad A, et al. Growth related oncogene alpha does not relate to inflammatory change in COPD. Eur Respir J 2005;26(Suppl 49):482s.
30. O'Shaunessy TC, Ansari TW, Barnes NC, et al. Inflammation in bronchial biopsies of subjects with chronic bronchitis, inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med 1997;155:852-7.
31. Gompertz S, Hill AT, Bayley DL, et al. Effect of expectoration on inflammation in induced sputum in alpha-1-antitrypsin deficiency. Respir Med 2006;100:1094-9.
32. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996;153:1530-5.
33. Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J 1995;8:1333-8.
34. Saetta M, Turato G, Maestrelli P, et al. Cellular and structural basis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1304-9.
35. Hill A, Campbell EJ, Hill SL, et al. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000;109:288-95.
36. Wise RA. The value of forced expiratory volume in one second decline in the assessment of chronic obstructive pulmonary disease progression. Am J Med 2006;119(10 Suppl):4-11.
37. Wright JL, Tai H, Wang R, et al. Cigarette smoke upregulates pulmonary vascular matrix metalloproteinases via TNF-alpha signaling. Am J Physiol Cell Biol Mol Physiol 2007;292:L125-33.
38. Sullivan AL, Stockley RA. Proteinases in COPD. In: Stockley RA, Rennard S, eds. Chronic obstructive pulmonary disease. Oxford: Blackwells, 2006:349-66.
39. Wilson DO, Rogers RM, Wright EC, et al. Body weight in chronic obstructive pulmonary disease: the National Institutes of Health intermittent positive pressure breathing trial. Am Rev Respir Dis 1989;139:1435-8.
40. Gray-Donaldson K, Gibbons L, Shappiro SH, et al. Nutritional status and mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;153:961-6.
41. Mador MJ. Muscle mass and not body weight predicts outcome in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:787-9.
42. Eid AA, Ionescu AA, Nixon LS, et al. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:1414-8.